Moderate

Transthyretin cardiac amyloidosis (ATTR-CM) — chronic management

Infiltrative cardiomyopathy · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Transthyretin cardiac amyloidosis is an increasingly recognised cause of heart failure with preserved ejection fraction in older adults, caused by myocardial deposition of misfolded transthyretin. Non-invasive diagnosis and disease-modifying stabilisers have transformed management.

Red flags

  • Syncope (conduction disease or autonomic failure)
  • Progressive heart failure despite diuretics
  • New high-grade AV block
  • Intracardiac thrombus on imaging
  • Rapid clinical decline suggesting AL amyloid

Assessment

Differential diagnosis

  • Light-chain (AL) amyloidosis
  • Hypertensive heart disease / LVH
  • Hypertrophic cardiomyopathy
  • HFpEF of other cause
  • Fabry disease
  • Aortic stenosis with LVH

Investigations

  • ECG (low voltages discordant with LV thickness, pseudo-infarct pattern)
  • Echo (increased wall thickness, granular myocardium, reduced strain with apical sparing)
  • Serum free light chains, serum/urine immunofixation to exclude AL
  • Bone scintigraphy (99mTc-DPD/PYP) Grade 2-3 cardiac uptake
  • Genetic testing to distinguish hereditary (variant) from wild-type ATTR
  • Cardiac MRI with late gadolinium enhancement where available

Management

  • Suspect ATTR-CM in older adults with HFpEF, bilateral carpal tunnel or LVH of unclear cause
  • Exclude AL amyloidosis with free light chains and immunofixation before interpreting a bone scan
  • Diagnose ATTR non-invasively with Grade 2-3 cardiac bone-scintigraphy uptake and negative monoclonal screen
  • Genotype to separate hereditary from wild-type disease and inform family screening
  • Start a TTR stabiliser (tafamidis) to slow disease progression
  • Manage heart failure with cautious diuresis, avoiding over-diuresis and hypotension
  • Use beta-blockers, ACEi/ARB and calcium blockers cautiously — often poorly tolerated
  • Avoid digoxin where possible owing to amyloid binding and toxicity risk
  • Anticoagulate for atrial fibrillation regardless of CHA2DS2-VASc given high thrombus risk
  • Consider pacing for conduction disease and assess arrhythmia burden
  • Screen relatives in hereditary ATTR
  • Arrange specialist amyloid-centre follow-up

Drugs & doses

Tafamidis 61 mg PO OD (free acid) as TTR stabiliser
Furosemide 20-80 mg PO OD titrated to congestion (cautious diuresis)
Apixaban 5 mg PO BD if atrial fibrillation present
Emerging: TTR silencers (patisiran, vutrisiran) in specialist use
Avoid digoxin and high-dose beta-blockers

Disposition

Refer to a specialist amyloidosis/cardiomyopathy centre; coordinate genetics and family screening. Heart failure follow-up with cautious decongestion.

Complications & pitfalls

  • Progressive restrictive heart failure
  • Conduction block requiring pacing
  • Atrial thrombus and embolism
  • Drug intolerance (hypotension, bradycardia)
  • Autonomic dysfunction and orthostatic hypotension

Exam pearls

  • A positive bone scan with a negative monoclonal screen is diagnostic of ATTR without biopsy
  • Always exclude AL amyloid first — it has a very different, urgent treatment pathway
  • Apical sparing on strain imaging ('cherry on top') is a classic clue
  • Bilateral carpal tunnel syndrome often precedes cardiac diagnosis by years
  • Tafamidis improves survival and reduces hospitalisation when started early

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.